Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics (NASDAQ: VRDN) announced the approval of stock options for 266,000 shares to five new employees. These Inducement Grants, made on June 1, 2022, are designed to encourage new hires and are outside the 2016 Equity Incentive Plan. The exercise price matches the stock's closing price on the grant date and will vest over four years, starting with 25% after one year. Viridian focuses on developing treatments for serious conditions like thyroid eye disease, with its leading product candidate VRDN-001 targeting IGF-1R.
Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in two fireside chats at upcoming conferences in New York. The first is at the Jefferies Healthcare Conference on June 8, 2022, at 11:30 am ET, followed by the JMP Securities Life Sciences Conference on June 15, 2022, at 3:30 pm ET. Investors can access live webcasts of both events via registration links. Viridian focuses on innovative therapies for serious diseases, with its lead program targeting thyroid eye disease.
Viridian Therapeutics (NASDAQ: VRDN) announced Phase 1/2 clinical trial updates for its lead product candidate, VRDN-001, targeting Thyroid Eye Disease (TED). Interim results show robust IGF-1 response with no significant adverse effects, suggesting the potential for lower dosing. The company ended Q1 2022 with $175 million in cash, expected to fund operations into 2024. R&D expenses increased to $17.7 million, contributing to a net loss of $25.7 million. The VRDN-002 trial is on track for top-line data in Q3 2022, aiming to enhance treatment convenience for TED patients.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced it will report financial results for Q1 2022, ending March 31, after market close on May 12, 2022. A conference call will take place at 4:30 p.m. ET on the same day, accessible via phone or webcast. The company's focus is on developing treatments for serious diseases, with lead candidate VRDN-001 targeting insulin-like growth factor-1 receptor for thyroid eye disease, and VRDN-002, an extended half-life anti-IGF-1R antibody for convenient subcutaneous administration.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will participate in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, starting at 4:30 p.m. ET. The conference will feature a corporate overview presentation. A live webcast and replay are available on Viridian's investor relations website.
Viridian focuses on innovative treatments for serious diseases, with its leading candidate, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease. The second candidate, VRDN-002, is designed for convenient subcutaneous administration.
Viridian Therapeutics (NASDAQ: VRDN) has secured a debt financing agreement with Hercules Capital for up to $75 million. The initial drawdown of $5 million has been completed, with additional funds contingent on milestones and lender approval. As of December 31, 2021, Viridian reported a cash position exceeding $197 million, expected to fund operations through 2024, excluding this new facility. The financing aims to enhance the company's operational flexibility while advancing clinical programs VRDN-001 and VRDN-002, targeting thyroid eye disease.
Viridian Therapeutics has initiated a Phase 1 clinical trial for VRDN-002, a monoclonal antibody designed to treat thyroid eye disease (TED). This trial involves 16 healthy volunteers receiving ascending doses of VRDN-002 to assess its safety and efficacy as a low-volume subcutaneous injection. Results are anticipated mid-year. This milestone supports Viridian's strategy to enhance patient care for TED, potentially allowing for at-home self-administration or treatment in a physician's office.
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm focused on treating serious diseases, will have its CEO, Jonathan Violin, participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 10:40 a.m. ET. This event highlights the company's efforts to advance new therapies, particularly VRDN-001, a monoclonal antibody for thyroid eye disease, and VRDN-002, a half-life extended treatment option. Interested parties can view the live webcast and replay on Viridian's website.
Viridian Therapeutics (NASDAQ: VRDN) reported financial results for Q4 and FY 2021, highlighting a strong cash position of $197 million to fund operations into 2024.
The company has two ongoing clinical trials for its IGF-1R antibodies, VRDN-001 and VRDN-002, targeting Thyroid Eye Disease (TED), with top-line data expected in Q2 and mid-2022, respectively.
Despite a net loss of $28.9 million in Q4 2021, this is an improvement from $90.7 million in the previous year, driven by reduced R&D expenses.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will report its financial results for the fourth quarter and full year ended December 31, 2021, on March 10, 2022, after market close. The management will host a conference call at 4:30 p.m. ET on the same day. Interested parties can listen by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (international) with conference ID: 13727096. The call will also be available via live webcast on the company's investor site. Viridian focuses on developing treatments for serious diseases, targeting insulin-like growth factor-1 receptor for thyroid eye disease.